Svenska  |  Site map  |  Contact

image

Press releases 2012 - 2011 - 2010 - 2009 - 2008 - 2007

  • 2007-10-01
    New CEO to Strengthen Moberg Derma’s Organization
    Read more
  • 2007-09-10
    Moberg Derma Reports Positive Phase II Results for Its K301 Product Candidate for the Treatment of Seborrheic Dermatitis
    Read more
  • 2007-09-10
    Moberg Derma Starts Recruiting Patients for Phase III Clinical Trial for Its K101 Product Candidate to Treat Nail Fungus (Onychomycosis)
    Read more
  • 2007-06-27
    Moberg Derma Receives Regulatory Approval to Start Clinical Phase III trial for a Novel Treatment of Nail Fungus (Onychomycosis)
    Read more
  • 2007-06-27
    Moberg Derma Raises SEK 27,7 Million to Fund Clinical Phase III trial for a Novel Treatment of Nail Fungus (Onychomycosis)
    Read more

Subscribe to information on Moberg Pharma

 
Contact Investor relations: 

Magnus Persson, IR 
Phone: +46 733 55 26 01
Email: magnus.persson@mobergpharma.se  
 
Peter Wolpert, CEO
Phone +46 8 522 307 00
 
Moberg Pharma AB (publ)
Gustavslundsvägen 42, 5 tr, SE-167 51 Bromma, Sweden
Phone: +46 8 522 30 700
info@mobergpharma.se